• Zum Hauptinhalt springen
  • Zum Footer springen
  • Deutsch - de
  • English - en

    SyNergy - Mu...

    • About
      • About us
      • Our Measures
      • Members
      • Cluster Management
      •  PhD & Postdoc representatives
      • Scientific Advisory Board
      •  International cooperation partners
      • Timeline
      •  Media Kit
      • Contact
    • News & Events
      • News
      • Events
      • In the News
      • Open Positions
    • Research
      • Publications
      • Our Research Focus
      • Technology Hubs
      • Research Spotlight
      • Research Data Management
      • Sustainability Initiative
      •  Code of Conduct
    • Science & Society
      • For Schools & Students
      • Public Events
      • Podcasts
      • Videos
    • Support for Diversity & Equity
      • Newcomer Center
      • Gender Equality Program
      • Early Career Investigator Program
    1. Home
    2. News & Events
    3. News
    4. Treating strokes: new therapy on the horizon
    News | 07/08/2024 | Press Release

    Treating strokes: new therapy on the horizon

    LMU researchers have identified a possible approach for breaking the vicious cycle of recurrent strokes.
     Arthur Liesz and Stefan Roth in the lab
    ©Boris Schmalenberger
    Stefan Roth & Arthur Liesz

    Recurrent strokes in the days and weeks after the initial event are a common problem in patients for whom arteriosclerosis was the original cause. An international team of researchers under the aegis of LMU University Hospital has now carried out a detailed investigation into why recurrent strokes occur so often. They discovered that DNA released from cells after the initial event induces an inflammatory response in the entire body, which – among other things – leads to a deterioration of arteriosclerotic plaques and thus to new vascular obstructions – a vicious cycle. The research team, which is led by Arthur Liesz, Professor at the Institute for Stroke and Dementia Research and member of the SyNergy Cluster of Excellence, has proposed a new therapy based on its findings, which involves breaking down the cell-free DNA by means of suitable drugs (DNase enzymes). The study results have now been published in the scientific journal Nature. If confirmed in humans, the findings could lead to improved stroke therapy.

    • Read the full press release on the website of LMU

    Participating Universities
     LMU logo in white
     TUM logo in white
    Partner Institutions
     Logo DZNE in white
    Helmholtz Munich logo in white 
     Logo Max Planck Gesellschaft 

    SyNergy is funded by the Deutsche Forschungsgemeinschaft (German Research Foundation) within the framework of the German Excellence Strategy (EXC 2145 SyNergy – ID 390857198). The Excellence Strategy promotes outstanding research at German universities. 

    Contact

    Munich Cluster for Systems Neurology (SyNergy)

    Feodor-Lynen-Str. 17
    81377 Munich
    +49 (0)89 4400-46497
    yüubgnybcјuipxјa+vfulyzedmi
    Editor login
    Imprint | Data-Safety